Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $59.15, demonstrating a -5.75% change from the preceding day’s closing price. This change lagged the S&P 500’s daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%.
Coming into today, shares of the company had gained 24.65% in the past month. In that same time, the Medical sector gained 3.09%, while the S&P 500 gained 0.92%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on November 3, 2025. The company is forecasted to report an EPS of $0.09, showcasing a 50% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $581.61 million, reflecting a 44.84% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.6 per share and revenue of $2.35 billion, indicating changes of +122.22% and +59.03%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts’ confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we’ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.28% lower. Hims & Hers Health, Inc. is holding a Zacks Rank of #4 (Sell) right now.
Investors should also note Hims & Hers Health, Inc.’s current valuation metrics, including its Forward P/E ratio of 105.22. Its industry sports an average Forward P/E of 40.64, so one might conclude that Hims & Hers Health, Inc. is trading at a premium comparatively.
Also, we should mention that HIMS has a PEG ratio of 4.29. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company’s anticipated earnings growth rate. The Medical Info Systems industry currently had an average PEG ratio of 3.33 as of yesterday’s close.
:max_bytes(150000):strip_icc()/Health-supplements-2e209f3fabd949c6bc75609e3885cbb9.png?w=360&resize=360,180&ssl=1 "This Is the #1 Workout Supplement To Boost Performance and Results")
